The bioinformatic work behind this article — the manuscript, the follow-up analysis, and the raw data — is public and ongoing. This article will be updated as new verified material warrants it, every addition dated and marked as an update.
The Pattern Behind the Pattern
In July 2026, a formal Correction/Retraction request to Nature — Vermeer & Louwen, an independent bioinformatic re-analysis of the earliest published SARS-CoV-2 patient data — documented seven anomalies in the raw sequencing files behind Zhou et al. (2020), the paper that first described the Wuhan outbreak. Follow-up work since then found more. Separately, and on a completely different evidentiary track, congressional testimony and FOIA releases from 2023-2026 show what the scientists who wrote the "natural origin" consensus were saying to each other in private while that consensus was being built. Laid side by side — not blended, each on its own evidentiary footing — one pattern emerges twice.
1. What the Manuscript Found
The full technical case is published separately.1 In brief, seven anomalies in BioProjects PRJNA605983 and PRJCA002163 — the raw sequencing repositories behind the first published description of SARS-CoV-2 — none of which appear in the original paper's methods or metadata:
Seven Findings, One Sentence Each
1. RBD-Fc clonality — the receptor-binding domain of the earliest patient sequences is 100% nucleotide-identical across 110 of 112 assemblies, against an expected ~0.17 mutations per copy under normal viral mutation rates over the claimed four months of circulation, and matches the architecture of a patent (CN111333704B) filed 62 days after the sample date.
2. Undisclosed CRISPR/SpCas9 experiment — guide-RNA scaffold reads in one library (WIV05) with spacers matching five mouse genes (Cd68, Sat1, Mecp2, Procr, and a chrX region) at 100% identity, absent from every MiSeq control run.
3. GPS metadata anomaly — 101 sample records, submitted as one batch in January 2021, carry coordinates for Walter Reed National Military Medical Center, Bethesda, while the text field for each still reads "China: Wuhan."
4. Star phylogeny — 83 of 115 internal branches across 111 sequenced WIV assemblies have lengths statistically indistinguishable from zero; calibrated against the nearest wild bat coronaviruses (ZC45/ZXC21), WIV branch lengths are 100 to 1,000 times shorter than genuine evolutionary distance in this region.
5. Restriction-enzyme signatures — the two spike insertions unique to SARS-CoV-2 (Insert 1 and Insert 4, which contains the furin cleavage site) carry flanking NcoI and dual NdeI sites consistent with directional molecular cloning; the two insertions SARS-CoV-2 shares with its nearest bat relative, RaTG13, carry no such signature.
6. Undisclosed co-processing of high-consequence pathogens — avian influenza H7N9 at 1,472× mean depth and 100% breadth in one library (WIV07-2, 297× the enrichment of a matched library from the same platform and period), and Nipah virus carrying infectious-clone markers (an HDV ribozyme and T7 terminator), present in two libraries and absent — zero reads across 134 million — in a third library on the identical platform, ruling out simple background contamination.
7. Platform mislabeling — four of five deep-sequenced libraries are recorded in NCBI's SRA metadata as "Illumina HiSeq," while file naming and depositor documentation confirm they were run on a different instrument (MGISEQ-2000RS).
2. What Came After the Manuscript
The manuscript itself is finished and formally submitted. The dataset was not fully exhausted by it. Working with Rogier Louwen after submission, and prompted at points by outside researchers and by readers' own follow-up questions, further screening of the same library that carried the strongest signal — WIV07-2 — turned up more.
A Genome's Worth of E. coli, Confirmed Two Independent Ways
Whole-genome alignment against E. coli K-12 found 3.33% of WIV07-2's reads mapping with 60.9% genome breadth and 44.5× mean depth — against 0.01% and 0.44% breadth in the matched negative-control library. A second, entirely independent method — Kraken2 k-mer taxonomic classification against the full Standard-8 reference database (bacteria, archaea, viral, human, UniVec) — found the same pattern from scratch: 13,638 Escherichia-classified reads in WIV07-2 against 2 in the control, with bacterial sequence making up 51.2% of all classified reads in that one library.
Two unrelated cloning-vector backbones — pBeloBAC11 and pExchange1, generic laboratory plasmids with no relationship to SARS-CoV-2 — were also found specifically enriched in the same library: 38-180× and 36-90× above every other sample respectively. A systematic search for physical junction reads — a single sequencing read spanning both the virus and this bacterial/vector material, which would prove the two were fused into one molecule — found none: 875 candidate reads, all resolved on inspection to known low-complexity artifacts (the viral genome's poly-A tail, a shared cassette sequence common to many commercial cloning vectors). The absence of a fused construct does not remove the finding; it only means the bacterial and vector material was present alongside the sample, not spliced into it.
The Same Institution, a Different Dataset, the Same Signature
An entirely separate WIV-associated dataset — public agricultural rice sequencing data, unrelated to the COVID-19 outbreak samples — was independently found by a different research team to contain a Merbecovirus infectious clone built on a pBAC-CMV cloning backbone traced to Zhengli Shi's own laboratory. Different BioProject, different year, different research team, same underlying signature: undisclosed synthetic-construct work moving through WIV-associated sequencing pipelines without appearing in any published methods section.
3. Designed to Leave No Trace
None of the signatures above are self-evidently visible without deliberately screening for them — no obvious splice scar, no marker anyone would trip over by accident. That is not incidental. It was, years before the outbreak, the explicitly stated research plan.
"Would Leave No Signatures of Purposeful Human Manipulation"
A federal grant proposal co-authored by Ralph Baric's collaborator Fang Li, funded through NIAID, described in Aim 3 the use of "infectious clone technology" to test which coronaviruses could spill over into humans. An FBI memorandum, written weeks into the pandemic and later released under FOIA, quoted the proposal and drew the direct implication: "The reason I am writing is that the experimental strategy proposed in Aim 3 ('infectious clone technology'), if performed using commercial or in-house gene synthesis to prepare the infectious clones, would leave no signatures of purposeful human manipulation."
This does not prove SARS-CoV-2 was built this way. It establishes that the specific technique capable of producing exactly the kind of subtle, statistically-detectable-but-not-visually-obvious signature documented in Finding 5 above was already a described, funded research method in the same international collaborator network years before the outbreak.
DEFUSE: The Proposal DARPA Turned Down
A 2018 research proposal, DEFUSE, described inserting human-compatible cleavage sites into bat coronavirus spike proteins as part of its experimental plan — the same category of modification documented at the furin cleavage site in Finding 5. Vincent Munster, of the Rocky Mountain Laboratories network connected to Erasmus MC through the Rotterdam collaborator chain,2 was a proposed partner. DARPA rejected the proposal, citing gain-of-function and dual-use risk. Whether any element of the proposed work was pursued through a different funding channel afterward has never been publicly resolved.
Open question, not established fact: a 13 August 2021 whistleblower complaint by Major Joseph Murphy to the Department of Defense Inspector General alleges continuing concern about this program. The complaint itself is an authentic, FOIA-confirmed document (DoD IG FOIA hotline report 23-F-0742). Its allegations are Murphy's own claims and are presented here as such — not as independently verified fact.
4. Private Doubt, Public Certainty
The pattern of knowing one thing privately and saying something calmer publicly is not unique to any one country's pandemic response.3 It runs, documented under oath, through the single most-cited scientific paper on the question of where SARS-CoV-2 came from.
"We Really Don't Have Any Hard Evidence One Way or the Other"
Kristian Andersen, lead author of "The Proximal Origin of SARS-CoV-2" — Nature Medicine, 17 March 2020, the paper most cited worldwide as evidence against a laboratory origin — to co-authors Eddie Holmes and Robert Garry, months after publication: "we really don't have any hard evidence one way or the other... we can't rule out that somebody actually put it in there... Our paper was pretty strong in saying 'there's no way,' but I have less confidence in that statement at this stage." In the same exchange, asked to estimate the odds themselves: Andersen, 70% natural / 30% lab. Holmes: 90/10, moving from an earlier 80/20.
Fauci Proposed the Paper Himself — Twice, With Email Evidence Both Times
On 31 January 2020, Fauci called Andersen directly and, per his own same-day email to Jeremy Farrar, told him "that as soon as possible he and Eddie Holmes should get a group of evolutionary biologists together to examine carefully the data... if everyone agrees with this concern, they should report it to the appropriate authorities." He repeated the request the next day on a conference call with eleven scientists, Fauci, Francis Collins, and NIH principal deputy director Lawrence Tabak. The paper that resulted from that request became Proximal Origin. Holmes and Rambaut privately nicknamed Fauci, Collins, and NIH leadership "the Bethesda Boys" — confirmed under oath by both Garry and Andersen as a reference to that group.
The Sentence That Was Added to Satisfy a Rejection, Not New Data
Nature rejected the manuscript on 20 February 2020 — not because it was too soft on ruling out a lab origin, but the opposite: a reviewer objected that its original, more open conclusion did not argue against the laboratory scenario strongly enough. Garry, under oath: "They thought that we came down too strongly on the side that the virus had been of possible lab origin." The sentence that ultimately anchored the paper's public reception — "we do not believe that any type of laboratory-based scenario is plausible" — was added afterward. Andersen, under oath, on when and why: "That was added to the final version... in response to the reviewers, our own thinking of the topic, and then getting it published in Nature Medicine, as opposed to Nature."
Two months later, the paper closed the loop it had opened. Collins to Fauci, 16 April 2020: "I hoped the Nature Medicine article... would settle this... Wondering if there is something NIH can do to help put down this very destructive conspiracy... Anything more we can do?" The next day, Fauci cited Proximal Origin from the White House podium as evidence against a lab origin.
Two Co-Authors Who Aren't Listed as Co-Authors
Fouchier and Koopmans — both gain-of-function researchers, both invited into the 1 February teleconference and the 8 February draft circulation alongside every named Proximal Origin author — do not appear as authors or listed contributors in the published paper. Congressional records and FOIA emails confirm they declined attribution because they "opposed scientific articles considering the lab leak theory at all." Koopmans went on to sit on the WHO's 2021 origins team, which called a lab origin "extremely unlikely" — without disclosing her uncredited role in shaping the paper that established that conclusion a year earlier.
5. Zhou Yusen: The Patent and the Death
Sixty-Two Days
Patent CN111333704B — an RBD-Fc fusion vaccine construct, application CN-202010112679-A, filed 24 February 2020 by Zhou Yusen and eleven co-inventors, assigned to two Academy of Military Sciences/PLA institutes and a Beijing biotech firm — matches the architecture found in Finding 1, in a patient sample collected 24 December 2019, sixty-two days earlier. Zhou Yusen died in May 2020, under circumstances that remain unclear. No further verified detail is available beyond that his death occurred within months of the sample match and the patent filing.
6. Not Over Yet
A DEFUSE-Proposed Partner, Indicted for Smuggling Biological Material — Six Years Later
In January 2026, Vincent Munster — the same researcher proposed as a DEFUSE partner in 2018 — was stopped at Detroit Metropolitan Airport returning from Paris after a nine-day stay in the Democratic Republic of Congo. A search found 113 vials in styrofoam coolers: 17 containing inactivated mpox virus, one containing varicella, two containing human DNA. He denied, according to the FBI, "categorically" carrying biological material. On 2 June 2026, the DOJ formally indicted Munster and a colleague, Claude Kwe, for smuggling biological material and making false statements — maximum penalty, five years.
The Question Still Being Avoided, Under Oath, in 2026
In sworn Senate testimony on 29 July 2026, Fauci again declined to answer direct questions about pre-pandemic gain-of-function funding. Ron Fouchier — his long-time collaborator on H5N1 gain-of-function research, and one of the two uncredited private contributors to Proximal Origin — was raised again specifically in connection with 2011 funding decisions. The accountability question this article opened with is not archival. It is still, six years later, being asked and still not being answered.
Two evidentiary tracks, kept deliberately separate, arrive at the same shape.
The forensic data cannot establish intent, and this dossier does not claim it does — 0 physical junction reads means the intact RBD-Fc construct itself was never found fused in patient material, only its statistical fingerprint. What the data shows is a pattern of undisclosed, synthetic-construct-grade laboratory material moving through the same pipeline that produced the first officially recognized COVID-19 patient samples. What the documents show, on their own separate footing, is a research network with a direct stake in exactly this kind of work, discussing privately what they would not say publicly, while shaping the public record that closed the question for five years. Neither track proves the other. Together, they stop looking like coincidence.
Sources
- Vermeer, J. & Louwen, R. "Seven Anomalies in the Earliest SARS-CoV-2 Sequencing Data: An Independent Bioinformatic Analysis of PRJNA605983." Zenodo, DOI 10.5281/zenodo.21410252, 2026; submitted to Nature as a formal Correction/Retraction request.
- Quay, S., Zhang, D., Jones, A. & Deigin, Y. "Nipah virus vector sequences in COVID-19 patient samples sequenced by the Wuhan Institute of Virology." arXiv:2109.09112, 2021.
- Jones, A., Zhang, D., Massey, S. & Nemzer, L. "Discovery of a novel merbecovirus DNA clone contaminating agricultural rice sequencing datasets from Wuhan, China." Journal of Bioinformatics and Systems Biology, January 2024.
- FBI internal memorandum, "[Suspect] Re: Follow up call," 23 April 2020, released via FOIA.
- DEFUSE proposal (DARPA HR00118S0017, 2018), reported by The Intercept, 23 September 2021.
- Major Joseph Murphy, complaint to the DoD Inspector General, 13 August 2021 (FOIA hotline report 23-F-0742).
- Andersen, K., Rambaut, A., Lipkin, W.I., Holmes, E. & Garry, R. "The Proximal Origin of SARS-CoV-2." Nature Medicine, 17 March 2020.
- Slack export "slack-drop-pm.pdf," released by Senate Homeland Security and Governmental Affairs Committee, paul.senate.gov/readingroom, 21 July 2026.
- Select Subcommittee on the Coronavirus Pandemic, "The Proximal Origin of a Cover-Up: Did the 'Bethesda Boys' Downplay a Lab Leak?", Majority Staff Report, 11 July 2023, oversight.house.gov.
- Collins-Fauci email correspondence, April 2020, obtained via FOIA.
- Daily Caller, 14 November 2022; U.S. Right to Know, "Timeline: The Proximal Origin of SARS-CoV-2."
- SureChEMBL patent record, CN111333704B / application CN-202010112679-A.
- U.S. Department of Justice, Eastern District of Michigan, indictment of Vincent Munster and Claude Kwe, 2 June 2026.
- U.S. Senate hearing transcript, 29 July 2026.
The Reference
500 botanicals — each with documented mechanisms, dosages, and synergy protocols. The complete reference for sovereign health practice.
The 500 Most Powerful Botanicals →